EMEA-001710-PIP03-17-M03

Table of contents

Key facts

Invented name
Zeposia
Active substance
Ozanimod (hydrochloride)
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0233/2021
PIP number
EMEA-001710-PIP03-17-M03
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of ulcerative colitis
Route(s) of administration
Oral use
Contact for public enquiries
Bristol-Myers Squibb Pharma EEIG

E-mail: medical.information@bms.com
Tel: +44 1423 53 3610

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating